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Background: There is considerable variation in progressive brain volume changes in schizophrenia. Whether
this is related to the clinical heterogeneity that characterizes the illness remains to be determined. This study
examines the relationship between change in brain volume over time and individual variation in
psychopathology, as measured by ﬁve continuous symptom dimensions (i.e. negative, positive, disorgani-
zation, mania and depression).
Methods: Global brain volume measurements from 105 schizophrenia patients and 100 healthy comparison
subjects, obtained at inclusion and 5-year follow-up, were used in this study. Symptom dimension scores
were calculated by factor analysis of clinical symptoms. Using linear regression analyses and independent-
samples t-tests, the relationship between symptom dimensions and progressive brain volume changes,
corrected for age, gender and intracranial volume, was examined. Antipsychotic medication, outcome and IQ
were investigated as potential confounders.
Results: In patients, the disorganization dimension was associated with change in total brain (β=−0.295,
p=0.003) and cerebellar (β=−0.349, pb0.001) volume. Furthermore, higher levels of disorganization
were associated with lower IQ, irrespective of psychiatric status (i.e. patient or control). In healthy
comparison subjects, disorganization score was not associated with progressive brain volume changes.
Conclusion: Heterogeneity in progressive brain volume changes in schizophrenia is particularly associated
with variation in disorganization. Schizophrenia patients with high levels of disorganization exhibit more
progressive decrease of global brain volumes and have lower total IQ. We propose that these patients form
a phenotypically and biologically homogenous subgroup that may be useful for etiological (e.g., genetic)
studies.© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
The presence of structural brain abnormalities in schizophrenia
has been well established (DeLisi et al., 1995, 1997; Shenton et al.,
2001). The most consistently reported abnormalities include enlarge-
ment of the ventricles and reductions of whole brain and gray matter
volume. Longitudinal neuroimaging studies have shown that these brain
volume abnormalities are progressive, although heterogeneity in brain
change over time is considerable across individual patients (Pantelis
et al., 2005; Hulshoff Pol and Kahn, 2008). In part, the heterogeneity
may be related to the broad diversity in signs and symptoms that
characterizes schizophrenia (DeLisi et al., 1998; Lieberman et al., 2001;
Andreasen et al., 2011). The aim of the present study is to examine
whether individual variation in lifetime rated schizophrenia symptom
dimensions is associatedwith heterogeneity in progressive brain volume
changes.+31 88 7555443.
vier OA license. Studies examining the relationship between symptomatology and
progressive brain volume changes are limited in number and have
yielded inconsistentﬁndings. In a review of progressive brain changes in
schizophrenia, Hulshoff Pol and Kahn (2008) report that more severe
negative symptomshave been linked tomore pronounced brain volume
loss, but that most studies examining clinical parameters in relation to
possible change in brain volume over time ﬁnd no such associations.
The lack of association may be due to clinical heterogeneity; indeed,
various approaches to deﬁne amore homogenous phenotype have been
employed. The use of symptoms to divide schizophrenia patients into
more uniform subgroups is the most common method (Buchanan and
Carpenter, 1997). More recently, factor-analytic studies have attempted
to characterize psychopathology in terms of quantitative symptom
dimensions. Liddle (1987) applied factor-analysis to symptoms rated
by the Comprehensive Assessment of Symptoms and History (CASH)
(Andreasen et al., 1992) and identiﬁed three symptom dimensions:
psychomotor poverty, reality distortion and disorganization. Other
studies using factor analysis to derive symptom dimensions report on
factor solutions including 4 to 11 factors, depending on the content of
the items included in the analyses (Peralta and Cuesta, 2001). While
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(in press) performed factor-analysis on CASH-items in 4286 patients,
their relatives and community controls. Lifetime-rated symptoms and
observational items of the CASH were used as they are considered to
better reﬂect genetic vulnerability and are less inﬂuenced by (antipsy-
chotic) treatment compared to present state symptoms. The analyses
revealed the presence of negative, positive, disorganized, depressive and
manic symptom dimensions.
The relationship between symptom dimensions and cross-sectional
brain volume measures has been studied previously. In a voxel based
morphometry (VBM) study in 99 schizophrenia patients and 113
matched healthy comparison subjects, Nenadic et al. (2010) reported
on volume reductions in prefrontal cortices and thalamus in patients
with predominantly negative symptoms, whereasmedial temporal and
cerebellar graymatter reductionsweremostly present in a disorganized
subgroup. Another VBM study, in 175 schizophrenia patients and 177
healthy comparison subjects, also reported on selective structural
correlates of symptom dimensions. A negative symptom dimension
was found to correlate with gray matter reductions in orbitofrontal,
prefrontal and temporal cortices and limbic structures, while disorga-
nization was associated with reductions in temporal, insular andmedial
prefrontal cortices (Koutsouleris et al., 2008). Findings on the positive
symptom dimension are inconsistent, as correlations with both de-
creased (Koutsouleris et al., 2008; Nesvåg et al., 2009) and increased gray
matter volume (Whitford et al., 2005) have been reported. To the best
of our knowledge, the relationship between lifetime rated schizophrenia
symptom dimensions and change in brain volume over time has not
been investigated.
The aim of this study is to explore the association between CASH
derived lifetime rated symptom dimensions and progressive brain
volume changes over a 5-year interval in schizophrenia patients and
healthy comparison subjects.Table 1
Demographic and clinical information.
Schizophrenia
patients (N=105)
Healthy comparison
subjects (N=100)
P
Age at baseline in years
(SD)
28.9 (10.6) 36.4 (13.5) b0.001
Gender (male/female) 81/24 69/29 0.190
Diagnosis, no. (%)
Schizophrenia 90 (85%)
Psychotic disorder
NOS
9 (9%)
Schizoaffective
disorder
6 (6%)
Cumulative medication
in HEQ (SD)a
2240 (1102)
CAN met and unmet
needs (SD)b
2.9 (2.3)
Parental level of
education in years
(SD)
12.30 (3.60) 11.98 (3.31) 0.533
WAIS IQ (SD)c 102.1 (14.4) 110.8 (9.3) b0.001
a Cumulative typical and atypical antipsychotic medication per year scan-interval in
haloperidol equivalent (HEQ).
b Camberwell Assessment of Needs (CAN).
c Wechsler Adult Intelligence Scale (WAIS).2. Methods
2.1. Subjects
For the present study a total of 105 patients (81 men, 24 women)
with schizophrenia and related spectrum disorders and 100 healthy
comparison subjects (69 men, 31 women) from two previously
published cohorts (van Haren et al., 2008; Cahn et al., 2009) were
included. For all subjects global brain volumemeasurements at inclusion
and 5-year follow-up and at least one CASH-interview with no more
than 20 missing items (25%) were available. The CASH interview
was included at baseline (N patients=14; N controls=5), one year
after baseline (N patients=14; N controls=5), or at 5-year follow-up
(N patients=77; N controls=90). All patients were recruited from the
Utrecht Schizophrenia Project and the First-Episode Schizophrenia
Research Program and were followed for a period of ﬁve years to
examine brain morphology in relation to clinical variables, such as
outcome, medication and cannabis use. All subjects provided written
consent prior to participation. Subjects with major medical or neuro-
logical illness were excluded. Patients were recruited from various out-
and inpatient clinics. The amount and type of medication prescribed
between inclusion and 5-year follow-up was recorded. Cumulative
dosage of antipsychotic medication in a haloperidol equivalent was
calculated using conversion rates as described by vanHaren et al. (2008).
Healthy comparison subjects had never been mentally ill and had no
ﬁrst-degree family member with a psychotic illness. Parental socioeco-
nomic status, expressed as the highest level of education completed by
one of the parents in years, was recorded for all subjects.
The statistical signiﬁcance of group-differences in demographic
characteristics was examined using analysis of variance (ANOVA) for
continuous and Chi-square tests for categorical variables. Demo-
graphic and clinical characteristics are provided in Table 1.2.2. Procedures and measures
2.2.1. CASH-based symptom dimensions
All subjects were assessed with the Comprehensive Assessment
of Symptoms and History (Andreasen et al., 1992). Factor analysis of
the lifetime-rated symptoms and observational items produced ﬁve
continuous symptom dimensions. Given the content of the items (see
Table 1 inDerks et al., in press), the symptomdimensionswere described
as “negative”, “positive”, “disorganization”, “mania” and “depression”.
The procedure to calculate factor scores for each of the ﬁve dimensions
was described in detail in Derks et al. (in press) Brieﬂy, a total of
67 lifetime-rated items were included in conﬁrmatory factor analyses
in a sample of 4286 schizophrenia and bipolar patients, relatives of
schizophrenia patients and community controls, recruited in the GROUP
study, Utrecht Schizophrenia Project, and the First-Episode Schizophre-
nia Research Program. For the present study, estimation of factor scores
was based on the entire sample of 4286 subjects, from which individual
dimension scores were extracted. It should be noted that subjects
with more than 20% but less than 25% missing items were included in
the analyses for this paper while they were excluded from Derks et al.
(in press).
2.2.2. Cognitive functioning
Global cognitive functioning, as measured by total IQ, was assessed
with four subtests of theDutch version of theWechsler Adult Intelligence
Scale (WAIS) (Stinissen et al., 1970): Vocabulary, Comprehension, Block
Design and Picture Arrangement. Mean raw scores were transformed
into the corresponding C-score of the WAIS for each subtest. Since
the WAIS has a total of 11 subtests, a proximate total sum of C-scores
was derived by adding the C-scores of the four subtests, divided by 4 and
multiplied by 11, as follows: proximate sum of C-scores=(C-score
of four subtests/4)×11. An estimated full-scale IQ was derived by
transforming the sum of C-scores into IQ-equivalents using transforma-
tion tables provided by the WAIS. IQ-scores were corrected for an
estimated IQ gain of 0.25 point per year for the number of years between
1971 and the date of the WAIS investigation (Flynn, 2009). IQ was
assessed in 82 patients and 95 controls. Mean IQ and range are provided
in Table 1.
2.2.3. Functional outcome
The Camberwell Assessment of Need (CAN; Phelan et al., 1995)
was obtained at various intervals during follow-up. The CAN is an
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mental illness. It consists of 24 items covering a wide range of human
needs, such as shelter and the company of other people, as well as
needs speciﬁc to people suffering from mental illness. CAN-data was
available for 95 out of 105 patients. A selection of items from the
CAN-interview at 5-year follow-up was used. Nine items that reﬂect
basic daily life skills were selected: accommodation, food, household
skills, self-care, daily activities, company of others, intimate relation-
ships, telephone and transport. The number of met and unmet needs
for these items was determined per patient and was used as a
measure of global functioning at 5-year follow-up (see Table 1).
2.2.4. MRI acquisition and measurements
Magnetic Resonance Imaging (MRI) scans were acquired on a 1.5 T
Philips NT scanner at inclusion and 5-year follow-up with a mean
(SD) MRI interval of 4.98 (0.45) years. All images were corrected for
inhomogeneities in themagneticﬁeld according to themethoddescribed
by Sled et al. (1998). In-house developed software was used to measure
total brain, gray and white matter, cerebellar en ventricle volumes. For
a description of MRI procedure and segmentation see Schnack et al.
(2001a,b), Hulshoff Pol et al. (2001) and Brouwer et al. (2010).
2.3. Statistical analysis
Mean global brain volumes at baseline and 5-year follow-up and
standard deviations were calculated. Volume change over time per
subject was calculated for all brain volumes by subtracting the volume
at baseline from the volume at follow-up. The percentage volume
change during scan interval was calculated by dividing the volume
change by the volume at baseline multiplied by 100%. Percentage of
volume change per year scan-interval was calculated by dividing the
percentage of volume change by the time between MRI scans in years.
Mean global brain volumes at baseline and 5-year follow-up and
the percentage of volume change per year scan-interval are summa-
rized in Table 2.
Brain volumedata and symptomdimension scoreswere examined for
outliers and normality of distribution. In patients, symptom dimension
scores were normally distributed. However, in controls, distributions of
dimension scores were not continuous, with the majority of the subjects
obtaining a very low score while a minority showed elevated dimension
scores.
To assess whether symptom dimension scores are associated
with brain volume change over time in schizophrenia patients, we
performed linear regression analyses in the patient sample in which
the percentage of volume change per year scan-interval for each of the
global brain volumes was the dependent variable. To correct for age,
gender and intracranial volume, these variables were included as
predictors. Dimension scoreswere included in themodel if this resulted
in a signiﬁcant improvement in the prediction of brain volume change,
according to forward stepwise analysis. As antipsychotic medication
may inﬂuence progressive brain volume change, the analyses wereTable 2
Global brain volumes at inclusion (T0) and 5-year follow-up (T5), and change in brain volu
Schizophrenia patients (N=105) Health
T0 T5 Δ (%) T0
Total brain 1269 (123.5) 1248 (122.8) −0.32 1274 (
Gray matter 622.6 (63.0) 598.1 (58.6) −0.78 607.4 (
White matter 488.4 (59.8) 490.5 (60.0) 0.11 508.9 (
Lat. ventricle 16.73 (9.23) 18.50 (10.40) 2.68 15.56 (
Third ventricle 1.13 (0.54) 1.23 (0.59) 2.27 1.06 (
Cerebellum 142.1 (15.1) 143.5 (15.2) 0.20 142.3 (
Note: Uncorrected mean (SD) brain volumes in mL; change in brain volume in percentage
signiﬁcance of group differences in brain volume change (time* status). In the analyses, t
volume. Lat. ventricle=lateral ventricle; Δ (%)=brain volume change in percentage per yerepeated with total cumulative medication during scan interval, in
haloperidol equivalent, as a covariate in a subgroup of 101 patients
for whom medication data was available. In addition, socioeconomic
status (i.e., parental level of education), global functional outcome (i.e.,
CAN) and cognitive functioning (i.e., estimated IQ)were investigated as
potential confounders for any signiﬁcant associations between symp-
tom dimensions and progressive change in global brain volumes.
Based on the observed effects in patients, the relationship between
disorganization andprogressive brain volume changeswas investigated
in the healthy comparison subjects. The healthy comparison sample
was categorized in two groups based on disorganization dimension
scores, because the distribution of dimension scoreswas not continuous,
asmentioned previously. Independent sample t-testswere conducted to
investigate the relationship between disorganization dimension scores
and brain volume change over time, corrected for age, gender and
intracranial volume, in the healthy comparison sample.
We performed multiple tests as we investigated the association
between change in six different brain volumes and ﬁve symptom
dimensions. We did not apply a strict Bonferroni correction as this
would control type-I error rate but would result in an increased type-
II error rate. A p-value of 0.008 was decided on so that type-I error
rate is controlled for the comparison of six brain volumes but should
be regarded as explorative for the ﬁve symptom dimensions. For the
analyses with a single dependent variable (i.e. total cumulative
medication, IQ and functional outcome), the p-value was set at 0.05.
3. Results
Progressive changes in global brain volumes were heterogeneous
across individual subjects. On average, total brain and cerebral gray
matter volume decreased over time and ventricle volumes increased
with patients exhibiting greater change than healthy comparison
subjects. Average cerebral white matter and cerebellar volume did
not change signiﬁcantly (see Table 2). In patients, progressive decline
of global brain volumes was signiﬁcantly associated with the level of
disorganization. Higher levels of disorganization were associated with
more pronounced decrease in total brain (β=−0.295, p=0.003) and
cerebellar volume (β=−0.349, pb0.001) (see Fig. 1). To ascertain that
the effect in total brain volume decline was not solely driven by the
decrease in cerebellar volume, a post-hoc regression analysis with total
brainminus cerebellar volume (i.e. total cerebral andbrainstemvolume)
and disorganization score was performed, which also demonstrated a
signiﬁcant association (β=−0.269, p=0.008). The positive, negative,
mania, and depression dimensions were not signiﬁcantly associated
with progressive change in any of the brain volumes (all p>0.05). Mean
(SD) symptom dimensions scores across the two subject groups are
provided in Table 3.
Total cumulative antipsychotic medication in haloperidol equiva-
lent between baseline and 5-year follow-up was not associated with
progressive brain volume change or symptom dimension scores.
Cognitive functioning (i.e., IQ) was not associated with progressivemes.
y control subjects (N=100) Time effect Time* status
T5 Δ (%) p p
126.6) 1263 (127.8) −0.18 b0.001 0.005
62.8) 596.7 (60.0) −0.34 b0.001 b0.001
65.8) 506.7 (65.1) −0.08 0.984 0.065
9.07) 17.10 (9.96) 1.72 b0.001 0.617
0.45) 1.08 (0.47) 0.52 0.001 0.032
12.8) 142.8 (13.2) 0.07 b0.001 0.071
per year; the statistical signiﬁcance of brain volume change (time) and the statistical
he percentage of brain volume change was corrected for age, gender and intracranial
ar.
Fig. 1. The percentage of brain volume change as a function of the level of disorganization
in schizophrenia patients. The x-axis represents the level of disorganization in a
standardized factor score. The y-axis represents the annual percentage of volume change
of (A) total brain and (B) cerebellum. The reference line indicates no change in
brain volume, i.e. the area above the reference line represents volume increase, below
volume decrease.
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associatedwith higher levels of disorganization (β=−0.258, p=0.021).
Functional outcome at 5-year follow-up was signiﬁcantly associated
with change in total brain (β=−0.350, p=0.001), cerebral gray matter
(β=−0.260, p=0.013) and lateral ventricle (β=0.281, p=0.007)
volume. Functional outcome was not signiﬁcantly associated with
symptom dimension scores. When total cumulative medication, socio-
economic status, functional outcome and cognitive functioning were
included as covariates in the regression analyses, the association between
disorganization and change in total brain and cerebellar volume remained
signiﬁcant.
As disorganization was signiﬁcantly associated with change in
global brain volumes in schizophrenia patients, this association wasTable 3
Mean (SD) symptom dimension scores.
Schizophrenia patients Healthy comparison subjects P
Mean (SD) Mean (SD)
Disorganization 0.72 (0.42) −0.25 (0.30) b0.001
Positive 0.93 (0.45) −0.57 (0.24) b0.001
Negative 0.60 (0.39) −0.27 (0 23) b0.001
Mania 0.55 (0.49) −0.36 (0.35) b0.001
Depression 0.49 (0.43) −0.47 (0.47) b0.001
Mean (SD) scores on each of the ﬁve symptoms dimensions across the subject groups;
and the statistical signiﬁcance of group-differences.also investigated in healthy controls. In the healthy comparison
sample, disorganization scores were not normally distributed. We
therefore created two groups based on a cut-off of the standardized
score of −0.250 for the disorganization dimension. The majority of
controls (N=81) scored below −0.250 on disorganization (mean
disorganization score=−0.36; SD=0.05), 19 control subjects scored
above−0.250 (mean disorganization score=0.25; SD=0.41). Healthy
comparison subjects with relatively high disorganization scores had
signiﬁcantly lower total IQ (t(93)=3.962, pb0.001, medium sized
effect: r=0.38) than those with low disorganization scores (see Fig. 2).
Progressive brain volume changes were not signiﬁcantly associated
with the level of disorganization in the healthy comparison subjects.4. Discussion
This study investigated the relationship between clinical hetero-
geneity and variation in progressive structural brain changes in
schizophrenia. To this end, the association between individual variation
in lifetime rated symptomatology, as measured by ﬁve continuous
symptom dimensions, and brain volume change over time was
examined in 105 schizophrenia patients and 100 healthy comparison
subjects. Our main ﬁnding is that greater severity of disorganization
symptoms is associated with more pronounced decrease of total brain
and cerebellar volume over time in schizophrenia patients. Negative,
positive, mania and depression symptom dimensions were not
associated with brain volume change over time.
Studies examining the relationship between schizophrenia symp-
tom dimensions and disease markers have found that early onset of
disease, long duration of illness (Salokangas et al., 2002) and antipsy-
chotic treatment resistance (Rodriguez et al., 1998) are particularly
associated with disorganization. This study adds that disorganization is
also associated with a pronounced decrease in global brain volume
over time. Furthermore, we found that disorganization is associated
with decreased intellectual functioning, consistent with a recent meta-
analysis showing that more severe disorganization symptoms predict
lower IQ (Dibben et al., 2009). Finally, studies examining the familiality
of symptom dimensions, have consistently shown that the disorganiza-
tion dimension is highly heritable (Rietkerk et al., 2008; McGrath et al.,
2009). Together, these ﬁndings suggest that not only may disorganiza-
tion be a biologically distinct feature of schizophrenia, the subgroup of
patients identiﬁed by high scores on the disorganization dimensionmay
also be biologically separate.
Indeed, patients with high levels of disorganization, low IQ and
relatively largeprogressive brain changes resemble the patients describedFig. 2. Mean IQ of healthy comparison subjects with low (n=19; mean IQ=103.4;
SD=9.1) versus high (n=81; mean IQ=112.4; SD=8.5) disorganization scores. The
difference is statistically signiﬁcant at pb0.001.
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particular hebephrenia (Hecker, 1871; Kraepelin, 1919; Kraam, 2009).
In fact, in a recent editorial arguing for the replacement of the
schizophrenia concept by hebephrenia, Taylor et al. (2010) show that
empirical data on psychopathology, clinical course, treatment response
and biological and genetic markers do not support the concept of
schizophrenia as a medical model. The authors argue that hebephrenia
is a more homogenous construct with distinctive and reliably identiﬁed
clinical features and conclude that hebephrenia is not merely a subtype
of schizophrenia: “It is schizophrenia” (Taylor et al., 2010).
A number of longitudinal studies have been performed in which
the association between brain volume change and outcomemeasures is
investigated. Milev et al. (2003) showed that small temporal lobe gray
matter volume at onset is associated with persistence of hallucinations
ﬁve years later. Reductions in graymatter volume over timewere found
to be associated with poor outcome, such as number of hospitalizations
(van Haren et al., 2007), and duration of psychosis (Cahn et al., 2009).
Ho et al. (2003) showed that patients with poor outcome had greater
increase in lateral ventricle volumes compared to patientswho recovered
well. They also showed that greater negative symptom severity at 3-year
follow-up was predicted by a greater decline in frontal lobeWM volume
and greater enlargement in frontal lobe CSF volume. We have not
found an association between change in brain volume and positive
and negative symptoms in patients with schizophrenia. This is slightly
counterintuitive; on the other hand, the results of previous studies are
also rather inconsistent. Our ﬁndings show that future studies should
include disorganization as a symptom dimension of interest as we ﬁnd
the strongest association between change in total brain volume and the
level of disorganization.
Progressive brain volume changes in schizophrenia are sometimes
attributed to the effects of antipsychotic medication (e.g., Lewis,
2011). Interestingly, patients with a greater severity of disorganiza-
tion symptoms — who, as our results indicate, showed the largest
loss of brain volume over time — did not receive higher doses of
antipsychotic medication than the other patients. Therefore, antipsy-
chotic medication cannot explain the loss of brain tissue in this
subgroup of patients. The association between progressive change in
global brain volumes and variation in symptomatology (i.e. level of
disorganization), in the absence of differential exposure to medica-
tion, suggests that the progressive brain changes are an integral part
of the pathophysiology of the illness. In fact, studies in individuals
at high genetic risk of schizophrenia show that progressive brain
changes predate not just antipsychotic treatment, but even illness
onset (McIntosh et al., 2011).
The neuropathologic mechanism underlying disorganization may
thus be different from the neuropathology leading to other symptom
dimensions. In a review of dopamine dysfunction in schizophrenia,
Howes and Kapur (2009) report that dopamine hyperfunction is closely
linked to the psychosis dimension, but predict that nonpsychotic
dimensions of schizophrenia would not show similar dopamine
abnormalities, thus dissociating psychosis from the other dimensions of
schizophrenia. The glutamate hypothesis may be better able to explain
schizophrenia features other than psychosis. Indeed, the concept of
glutamate dysfunction in schizophrenia originates from observations
that drugs acting on the glutamate N-methyl-D-aspartate (NMDA)
receptor (e.g. phenylcyclidine, ketamine) also induce the cognitive
and negative features of schizophrenia, while dopamine agonists only
produce positive (psychotic) symptoms (Krystal et al., 1994). Dysfunc-
tion of the glutamatergic system, through NMDA-hypofunction,
may also account for the progressive brain changes in schizophrenia:
high extracellular concentrations of glutamate cause excessive calcium
inﬂux through NMDA-channels, resulting in cell damage and cell
death. Moreover, glutamate-induced neurotoxicity can be reversed
by NMDA receptor antagonists in neuronal cultures. Sustained NMDA-
hypofunction may thus lead to not only neurochemical but also
neuroplastic changes in the brain (Gunduz-Bruce, 2009).Interestingly, there is some evidence from genetic studies that the
glutamatergic system is involved in the disorganization dimension.
In a genome wide linkage study, an association was found between a
factor-analytically derived schizophrenia subtype with severe disor-
ganization and negative symptoms and a susceptibility locus on
chromosome 1q23-25 (Holliday et al., 2009). The best-studied gene in
that region is the regulator of G protein signaling 4 (RGS4) gene, which
is involved in glutamate systems and is thought to have downstream
effects on the NMDA receptor (Volk et al., 2010). RGS4 expression is
downregulated in the prefrontal cortex and superior temporal gyrus in
schizophrenia (Prasad et al., 2005). Furthermore, genetic variation in
RGS4has been associatedwith brain volumealterations in schizophrenia
patients and healthy subjects (Bowden et al., 2007). Thus, dysregulation
of the glutamate systemmay, possibly through genetic variation inRGS4,
explain the association between disorganization and progressive brain
volume decline in schizophrenia.
The association between disorganization and progressive decrease
of cerebellar volume is particularly interesting in light of the concept
of “cognitive dysmetria” (Andreasen et al., 1998). In this model, all
schizophrenia symptoms are secondary to a core cognitive deﬁcit,
resulting from a disruption in brain circuitry involving the cerebellum.
Alterations in cerebellar volume have been associated with disorgani-
zation symptoms previously. In a cross-sectional study, Nenadic et al.
(2010) found cerebellar volume deﬁcits in a disorganized subgroup
of 99 chronic stable schizophrenia patients. However, evidence for
cerebellar abnormalities in schizophrenia is inconclusive (Picard et al.,
2008) and the present study did not establish decline of cerebellar
volume in schizophrenia patients versus healthy comparison subjects.
Onepossible explanation for these inconsistencies is that only a subgroup
of schizophrenia patients (i.e. disorganized patients) exhibits cerebellar
volume change.
Some limitations should be taken into account when interpreting
our ﬁndings. First, this study examined only global, and not regional,
changes in brain volumes. Second, there was large heterogeneity with
respect to duration of illness and age. Third, only a small number of
healthy comparison subjects (n=19) had relatively high disorgani-
zation scores, mandating caution when interpreting the association
between disorganization dimension score and cognitive functioning
in healthy individuals. Finally, in the majority of the subjects the
CASH interview was completed at 5-year follow-up. Therefore, the
direction of causality cannot be determined and it remains unre-
solved how the association between disorganization and progressive
brain volume changes arises.
In conclusion, we found that heterogeneity in progressive brain
volume changes in schizophrenia is particularly associated with the
level of disorganization. Patients with high levels of disorganization
exhibited a larger decrease in global brain volumes over time and are
also characterized by lower total IQ. We propose that these patients
form a biologically and genetically distinct subgroup of schizophrenia
patients. The identiﬁcation of this subgroup of patients will facilitate
detection of causal genetic factors in schizophrenia.
Role of funding source
The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Contributors
Authors WC, RSK HHP and NEMvH designed the study and wrote the protocol.
Authors GC and EMD analyzed the data. Authors HS, HHP and NEMvH designed the
MRI segmentation procedures. Authors GC, EMD, RSK and WC wrote the manuscript.
All authors contributed to and have approved the ﬁnal manuscript.
Conﬂict of interest
The authors report no conﬂicts of interest.
Acknowledgments
Dr. E.M. Derks is supported by the Netherlands Scientiﬁc Organization (NWO; project
number 451-080-010).
176 G. Collin et al. / Schizophrenia Research 138 (2012) 171–176References
Andreasen, N.C., Flaum, M., Arndt, S., 1992. The Comprehensive Assessment of
Symptoms and History (CASH). An instrument for assessing diagnosis and
psychopathology. Arch. Gen. Psychiatry 49 (8), 615–623.
Andreasen, N.C., Paradiso, S., O'Leary, D.S., 1998. “Cognitive dysmetria” as an integrative
theory of schizophrenia: a dysfunction in cortical–subcortical–cerebellar circuitry?
Schizophr. Bull. 24 (2), 203–218.
Andreasen, N.C., Nopoulos, P., Magnotta, V., Pierson, R., Ziebell, S., Ho, B.-C., 2011.
Progressive brain change in schizophrenia: a prospective longitudinal study of
ﬁrst-episode schizophrenia. Biol. Psychiatry 70 (7), 672–679.
Bowden, N.A., Scott, R.J., Tooney, P.A., 2007. Altered expression of regulator of G-protein
signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia.
Schizophr. Res. 89 (1–3), 165–168.
Brouwer, R.M., Hulshoff Pol, H.E., Schnack, H.G., 2010. Segmentation of MRI brain scans
using non-uniform partial volume densities. Neuroimage 49 (1), 467–477.
Buchanan, R.W., Carpenter, W.T., 1997. The neuroanatomies of schizophrenia.
Schizophr. Bull. 23 (3), 367–372.
Cahn, W., Rais, M., Stigter, F.P., van Haren, N.E.M., Caspers, E., Hulshoff Pol, H.E., Xu, Z.,
Schnack, H.G., Kahn, R.S., 2009. Psychosis and brain volume changes during the
ﬁrst ﬁve years of schizophrenia. Eur. Neuropsychopharmacol. 19 (2), 147–151.
DeLisi, L.E., Hoff, A.L., Sakuma, M., Kushner, M., Lee, G., Kantawala, K., Shedlack, K.,
Smith, A.M., Tew, W., Grimson, R., 1995. A prospective follow-up study of brain
morphology and cognition in 1st episode schizophrenic patients. Biol. Psychiatry
38, 349–360.
DeLisi, L.E., Grimson, R., Sakuma, M., Tew, W., Kushner, M., Hoff, A.L., 1997.
Schizophrenia as a chronic active brain process: a study of progressive brain
structural change subsequent to the onset of schizophrenia. Psychiatry research.
Neuroimaging 74, 129–140.
DeLisi, L.E., Sakuma, M., Ge, S., Kushner, M., 1998. Association of brain structural change
with the heterogeneous course of schizophrenia from early childhood through ﬁve
years subsequent to a ﬁrst hospitalization. Psychiatry Res. 84 (2–3), 75–88.
Derks, E.M., Allardyce, J., Boks, M.P., Vermunt, J.K., Hijman, R., Ophoff, R.A., in press.
Kraepelin was right: a latent class analysis of symptom dimensions in patients and
controls. Schizophr. Bull. (September 30): 1–11. doi: 10.1093/schbul/sbq103.
Dibben, C.R.M., Rice, C., Laws, K., McKenna, P.J., 2009. Is executive impairment
associated with schizophrenic syndromes? A meta-analysis. Psychol. Med. 39 (3),
381–392.
Flynn, J.R., 2009. The WAIS-III and WAIS-IV: Daubert motions favor the certainly false
over the approximately true. Appl. Neuropsychol. 16 (2), 98–104.
Gunduz-Bruce, H., 2009. The acute effects of NMDA antagonism: from the rodent to the
human brain. Brain Res. Rev. 60 (2), 279–286.
Hecker, E., 1871. Die hebephrenie: ein beitrag zur klinischen Psychiatrie. Arch. Pathol.
Anat. Physiol. Klin. Med. 52, 394–429.
Ho, B.-C., Andreasen, N.C., Nopoulos, P., Arndt, S., Magnotta, V., Flaum, M., 2003.
Progressive structural brain abnormalities and their relationship to clinical
outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.
Arch. Gen. Psychiatry 60 (6), 585–594.
Holliday, E.G., McLean, D.E., Nyholt, D.R., Mowry, B.J., 2009. Susceptibility locus on
chromosome 1q23-25 for a schizophrenia subtype resembling deﬁcit schizophrenia
identiﬁed by latent class analysis. Arch. Gen. Psychiatry 66 (10), 1058–1067.
Howes, O.D., Kapur, S., 2009. The dopamine hypothesis of schizophrenia: version III—the
ﬁnal common pathway. Schizophr. Bull. 35 (3), 549–562.
Hulshoff Pol, H.E., Schnack, H.G., Mandl, R.C.W., van Haren, N.E.M., Koning, H., Collins,
L., Evans, A.C., Kahn, R.S., 2001. Focal gray matter density changes in schizophrenia.
Arch. Gen. Psychiatry 58 (12), 1118–1125.
Hulshoff Pol, H.E., Kahn, R.S., 2008. What happens after the ﬁrst episode? A review of
progressive brain changes in chronically ill patients with schizophrenia. Schizophr.
Bull. 34 (2), 354–366.
Koutsouleris, N., Gaser, C., Jäger, M., Bottlender, R., Frodl, T., Holzinger, S., Schmitt,
G.J.E., Zetzsche, T., Burgermeister, B., Scheuerecker, J., Born, C., Reiser, M., Möller,
H.-J., Meisenzahl, E.M., 2008. Structural correlates of psychopathological symptom
dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage 39
(4), 1600–1612.
Kraam, A., 2009. Classic text no. 77 ‘Hebephrenia. A contribution to clinical psychiatry’
by Dr. Ewald Hecker in Gorlitz (1871). Hist. Psychiatry 20 (1), 87–106.
Kraepelin, E., 1919. Dementia-Praecox and Paraphrenia (translated by Barkley RM).
Huntington, New York, NY.
Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger,
G.R., Bowers Jr., M.B., Charney, D.S., 1994. Subanesthetic effects of the noncompe-
titive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual,
cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (3), 199–214.
Lewis, D.A., 2011. Antipsychotic medications and brain volume: do we have cause for
concern? Arch. Gen. Psychiatry 68 (2), 126–127.
Liddle, P.F., 1987. The symptoms of chronic schizophrenia. A re-examination of the
positive–negative dichotomy. Br. J. Psychiatry 151 (2), 145–151.
Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D., Bilder, R., 2001.
Longitudinal study of brain morphology in ﬁrst episode schizophrenia. Biol.
Psychiatry 49 (6), 487–499.McGrath, J.A., Avramopoulos, D., Lasseter, V.K., Wolyniec, P.S., Fallin, M.D., Liang, K.-Y.,
Nestadt, G., Thornquist, M.H., Luke, J.R., Chen, P.-L., Valle, D., Pulver, A.E., 2009.
Familiality of novel factorial dimensions of schizophrenia. Arch. Gen. Psychiatry 66
(6), 591–600.
McIntosh, A.M., Owens, D.C., Moorhead, W.J., Whalley, H.C., Stanﬁeld, A.C., Hall, J.,
Johnstone, E.C., Lawrie, S.M., 2011. Longitudinal volume reductions in people at
high genetic risk of schizophrenia as they develop psychosis. Biol. Psychiatry 69
(10), 953–958.
Milev, P., Ho, B.-C., Arndt, S., Nopoulos, P., Andreasen, N.C., 2003. Initial magnetic
resonance imaging volumetric brain measurements and outcome in schizophrenia:
a prospective longitudinal study with 5-year follow-up. Biol. Psychiatry 54 (6),
608–615.
Nenadic, I., Sauer, H., Gaser, C., 2010. Distinct pattern of brain structural deﬁcits in
subsyndromes of schizophrenia delineated by psychopathology. Neuroimage 49
(2), 1153–1160.
Nesvåg, R., Saetre, P., Lawyer, G., Jönsson, E.G., Agartz, I., 2009. The relationship
between symptom severity and regional cortical and grey matter volumes in
schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (3), 482–490.
Pantelis, C., Yücel, M., Wood, S.J., Velakoulis, D., Sun, D., Berger, G., Stuart, G.W., Yung,
A., Philips, L., McGorry, P.D., 2005. Structural brain imaging evidence for multiple
pathological processes at different stages of brain development in schizophrenia.
Schizophr. Bull. 31 (3), 672–696.
Peralta, V., Cuesta, M.J., 2001. How many and which are the psychopathological
dimensions in schizophrenia? Issues inﬂuencing their ascertainment. Schizophr.
Res. 49 (3), 269–285.
Phelan, M., Slade, M., Thornicroft, G., Dunn, G., Holloway, F., Wykes, T., Strathdee, G.,
Loftus, L., McCrone, P., Hayward, P., 1995. The Camberwell Assessment of Need:
the validity and reliability of an instrument to assess the needs of people with
severe mental illness. Br. J. Psychiatry 167 (5), 589–595.
Picard, H., Amado, I., Mouchet-Magas, S., Olié, J.-P., Krebs, M.-O., 2008. The role of the
cerebellum in schizophrenia: an update of clinical, cognitive, and functional
evidences. Schizophr. Bull. 34 (1), 155–172.
Prasad, K.M.R., Chowdari, K.V., Nimgaonkar, V.L., Talkowski, M.E., Lewis, D.A.,
Keshavan, M.S., 2005. Genetic polymorphisms of the RGS4 and dorsolateral
prefrontal cortex morphometry among ﬁrst episode schizophrenia patients. Mol.
Psychiatry 10 (2), 213–219.
Rietkerk, T., Boks, M.P.M., Sommer, I.E., Liddle, P.F., Ophoff, R.A., Kahn, R.S., 2008. The
genetics of symptom dimensions of schizophrenia: review and meta-analysis.
Schizophr. Res. 102 (1–3), 197–205.
Rodriguez, V.M., Catalina, M.L., García-Noblejas, J.A., Cuesta, P., 1998. Schizophrenic
syndromes and clozapine response in treatment-resistant schizophrenia. Psychiatry
Res. 77 (1), 21–28.
Salokangas, R.K.R., Honkonen, T., Stengård, E., Koivisto, A.-M., 2002. Symptom
dimensions and their association with outcome and treatment setting in long-
term schizophrenia. Results of the DSP project. Nord. J. Psychiatry 56 (5), 319–327.
Schnack, H.G., Hulshoff Pol, H.E., Baaré, W.F., Staal, W.G., et al., 2001a. Automated
separation of gray and white matter from MR images of the human brain.
Neuroimage 13 (1), 230–237.
Schnack, H.G., Hulshoff Pol, H.E., Baaré, W.F., Viergever, M.A., et al., 2001b. Automatic
segmentation of the ventricular system from MR images of the human brain.
Neuroimage 104 (1), 95–104.
Shenton, M.E., Dickey, C.C., Frumin, M., McCarley, R.W., 2001. A review of MRI ﬁndings
in schizophrenia. Schizophr. Res. 49 (1–2), 1–52.
Sled, J.G., Zijdenbos, A.P., Evans, A.C., 1998. A nonparametric method for automatic
correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17 (1),
87–97.
Stinissen, J., Willems, P.J., Coetsier, P., Hulsman, W.L.L., 1970. Handleiding bij de
Nederlandstalige bewerking van de Wechsler adult intelligence scale (W.A.I.S.).
Aanvullende normering van de WAIS voor de leeftijdsgroep van 55 tot 64 jaar
(WAIS-NL 1970). Swets & Zeitlinger, Amsterdam/Lisse.
Taylor, M.A., Shorter, E., Vaidya, N.A., Fink, M., 2010. The failure of the schizophrenia
concept and the argument for its replacement by hebephrenia: applying the
medical model for disease recognition. Acta Psychiatr. Scand. 122 (3), 173–183.
van Haren, N.E.M., Hulshoff Pol, H.E., Schnack, H.G., Cahn, W., Brans, R., Carati, I., Rais,
M., Kahn, R.S., 2008. Progressive brain volume loss in schizophrenia over the
course of the illness: evidence of maturational abnormalities in early adulthood.
Biol. Psychiatry 63 (1), 106–113.
van Haren, N.E.M., Hulshoff Pol, H.E., Schnack, H.G., Cahn, W., Mandl, R.C.W., Collins, D.L.,
Evans, A.C., Kahn, R.S., 2007. Focal gray matter changes in schizophrenia across the
course of the illness: a 5-year follow-up study. Neuropsychopharmacology 32 (10),
2057–2066.
Volk, D.W., Eggan, S.M., Lewis, D.A., 2010. Alterations in metabotropic glutamate
receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in
schizophrenia. Am. J. Psychiatry 167 (12), 1489–1498.
Whitford, T.J., Farrow, T.F.D., Gomes, L., Brennan, J., Harris, A.W.F., Williams, L.M., 2005.
Grey matter deﬁcits and symptom proﬁle in ﬁrst episode schizophrenia. Psychiatry
Res. 139 (3), 229–238.
